Evanguelos Xylinas
Overview
Explore the profile of Evanguelos Xylinas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
276
Citations
4128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gabriel P, Gauthier H, Xylinas E, Hermieu J, Desgrandchamps F, Hennequin C, et al.
Clin Genitourin Cancer
. 2025 Mar;
23(2):102312.
PMID: 40023937
Purpose: Emerging therapies including anti-PD-(L)1 immunotherapy have changed paradigms of treatment and improved oncological outcomes of advanced/metastatic urothelial carcinoma (mUC) patients. An emerging challenge in this setting is the management...
2.
Houede N, Chevallier T, Audenet F, Thibault C, Neuzillet Y, Abraham C, et al.
J Clin Oncol
. 2025 Feb;
:JCO2500179.
PMID: 39951246
Purpose: After radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin +...
3.
Ouzaid I, Fatica R, Herts B, McLennan G, Remer E, Xylinas E, et al.
Fr J Urol
. 2025 Jan;
35(3):102854.
PMID: 39826753
Objective: To analyze clinical and radiological features and trends in the management pattern of renal angiomyolipomas (AML) in a tertiary care center over a 30-year period. Patients And Methods: We...
4.
Daneshmand S, Kamat A, Shore N, Meeks J, Galsky M, Jacob J, et al.
Urol Oncol
. 2025 Jan;
PMID: 39818460
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review...
5.
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, et al.
BJU Int
. 2025 Jan;
PMID: 39797535
Objective: To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort of patients with high-risk and very-high-risk non-muscle-invasive bladder cancer (NMIBC) after previous...
6.
Rai B, Parmar K, Pradere B, Capoun O, Soukup V, Gontero P, et al.
Eur Urol Oncol
. 2025 Jan;
PMID: 39779382
Background And Objective: Given the uncertainty regarding the role of radical nephroureterectomy (RNU) as part of a multimodal treatment strategy for upper tract urothelial carcinoma (UTUC) patients with cN+ disease,...
7.
8.
Roumiguie M, Seisen T, Masson-Lecomte A, Prost D, Allory Y, Xylinas E, et al.
Fr J Urol
. 2024 Nov;
34(12):102722.
PMID: 39581669
Introduction: The purpose of this study was to propose an update of the French guidelines from the national committee ccAFU on upper tract urothelial carcinomas (UTUC). Methods: A systematic Medline...
9.
Roumiguie M, Leon P, Xylinas E, Allory Y, Audenet F, Bajeot A, et al.
Fr J Urol
. 2024 Nov;
34(12):102742.
PMID: 39581667
Objective: To update the CCAFU recommendations for the management of non-muscle invasive bladder cancer (NMIBC). Methods: A systematic review (Medline) of the literature from 20222024 was performed, taking into account...
10.
Roumiguie M, Marcq G, Neuzillet Y, Bajeot A, Allory Y, Sargos P, et al.
Fr J Urol
. 2024 Nov;
34(12):102741.
PMID: 39581664
Objective: To update the CCAFU recommendations for the management of muscle-invasive bladder cancer (MIBC). Methods: A systematic review (Medline) of the literature from 2022 to 2024 was carried out, taking...